Bullish indicating open at $55-$60, IPO prices at $37
Inozyme Pharma Inc. (INZY) stock has tumbled to a 52-week low, touching down at $0.98, representing a stark contrast to its 52-week high of $7.79. According to InvestingPro analysis, the company faces a challenging period marked by a significant downturn in its market valuation, now standing at approximately $67 million. Over the past year, Inozyme Pharma has seen its stock price plummet, with a staggering 1-year change of -83%, reflecting investor concerns and a bearish outlook on the company’s performance. While the company maintains a healthy cash position that exceeds its debt obligations, analysts have set price targets ranging from $7 to $23, suggesting potential upside despite current market sentiment. This latest price level underscores the difficulties Inozyme Pharma has encountered in the market, as shareholders bear witness to a precipitous drop from previous valuations. InvestingPro subscribers can access 13 additional key insights about INZY’s financial health and future prospects.
In other recent news, Inozyme Pharma Inc. reported promising interim results from its ENERGY 1 trial and Expanded Access Program, assessing the investigational drug INZ-701 in infants and young children with ENPP1 Deficiency. The data showed improvements in survival rates, heart function, and reductions in arterial calcifications, with no serious treatment-related adverse events. Piper Sandler adjusted its price target for Inozyme Pharma to $23 from $30 while maintaining an Overweight rating, citing confidence in the company’s operations and the potential of INZ-701 to generate significant revenue. H.C. Wainwright maintained a Buy rating with a $16 price target, highlighting regulatory progress for INZ-701, which has received orphan drug designation and other designations from the FDA and EMA. Raymond (NSE:RYMD) James reduced its price target to $24 from $26, maintaining an Outperform rating, while expressing optimism about the upcoming ENERGY 2 study despite concerns about anti-drug antibodies. The ENERGY 3 pivotal trial for pediatric patients with ENPP1 Deficiency has completed enrollment, with topline data expected in early 2026. Inozyme is also preparing for its ASPIRE pivotal trial, focusing on ABCC6 Deficiency, with plans to initiate the trial in early 2026. These developments reflect Inozyme’s ongoing efforts to address unmet medical needs in rare diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.